06Path to profitability metrics including operating expense leverage and timeline to sustained positive operating cash flow
07Ablation systems and disposables (estimated 60-65% of revenue): RF and cryoablation consoles, single-use clamps, probes, and catheters used in open and thoracoscopic AFib procedures
08AtriClip LAA exclusion devices (estimated 30-35%): Single-use clips for left atrial appendage closure during cardiac surgery to reduce stroke risk
growth - AtriCure attracts investors seeking exposure to high-growth medical device markets with strong demographic tailwinds (aging…
Rising interest rates have modest negative impact through two channels: (1) higher cost of capital for hospitals making equipment purchasing…
Watch on earnings: U.S. cardiac surgery procedure volumes (CABG, valve replacement) as proxy for addressable market size and concomitant ablation opportunity, Medicare reimbursement rates for CPT codes 33254-33259 (surgical ablation procedures) and 33340 (LAA exclusion), Quarterly ablation system placements and active hospital account count, indicating sales force effectiveness.
One Sentence Summary:
AtriCure: the story is balanced — u.s.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
